On the Record · Biogen
Biogen acquisitions, on the record
The businesses Biogen bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
ReataWord for word“On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.” 10-K for 2023 | acquisition | On September 26, 2023 | — |
Samsung BioepisWord for word“The decrease in other income, net was primarily due to the pre-tax gain of $1.5 billion recorded in 2022 related to the sale of our equity interest in Samsung Bioepis, partially offset by a pre-tax charge of $900.0 million, plus settlement fees and expenses, related to a litigation settlement agreement” 10-K for 2023 | divestiture | 2022 | pre-tax gain of $1.5 billion |
125 Broadway building and land parcelWord for word“In September 2022 we completed the sale of our building and land parcel located at 125 Broadway.” 10-K for 2023 | divestiture | In September 2022 | — |
HI-BioWord for word“On July 2, 2024, we completed the acquisition of HI-Bio.” 10-K for 2024 | agreed acquisition | On July 2, 2024 | — |
rare pediatric disease priority review voucherWord for word“In consideration for the PRV we received a cash payment of $103.0 million upon the closing of the PRV purchase, of which approximately $14.4 million was paid to Ionis.” 10-K for 2024 | divestiture | — | $103.0 million |
Samsung Bioepis equity interestWord for word“In April 2024 we received $437.5 million from Samsung BioLogics related to the sale of our equity interest in Samsung Bioepis.” 10-K for 2024 | divestiture | In April 2024 | $437.5 million |
FAMPYRA and related assets from AcordaWord for word“On July 10, 2024, Merz Therapeutics announced that its subsidiary Merz Pharmaceuticals LLC had completed the acquisition of FAMPYRA, and related assets from Acorda.” 10-K for 2024 | divestiture | On July 10, 2024 | — |
Alcyone Therapeutics, Inc.Word for word“In November 2025 we completed the acquisition of all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms.” 10-K for 2025 | acquisition | In November 2025 | — |
TOFIDENCE U.S. regulatory and commercial rights (sold to Organon)Word for word“In March 2025 we completed the sale of our regulatory and commercial rights in the U.S. for TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, to Organon.” 10-K for 2025 | divestiture | In March 2025 | — |
BYOOVIZ and OPUVIZ remaining commercial rights in EuropeWord for word“In October 2025 we completed the sale of our remaining commercial rights to two ophthalmology assets in Europe: BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA.” 10-K for 2025 | divestiture | In October 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $0 | $1.03 billion |
| 2017-12-31 | $0 | $1.27 billion |
| 2018-12-31 | $0 | $1.08 billion |
| 2019-12-31 | $744.4 million | $117.5 million |
| 2020-12-31 | — | $0 |
| 2022-12-31 | — | $0 |
| 2023-12-31 | $6.93 billion | $464.5 million |
| 2024-12-31 | $1.07 billion | — |
Deal filings since 2016
- 2026-05-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-05-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2026-03-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-08-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-09-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-07-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-02-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Biogen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.